Inventor · disambiguated record
Aiping H. Young
Also filed as: YOUNG AIPING · YOUNG AIPING H
19 granted patents·14 pending applications·213 citations·filing 1997–2016
94Inventor score
Files withGENESENSE TECHNOLOGIES INC12LORUS THERAPEUTICS INC6APTOSE BIOSCIENCES INC4YOUNG AIPING H3HUESCA MARIO2
Top patents by PatentIndex Score
33 records- 0186US8394815B22,4,5-trisubstituted imidazoles and their use as anti-microbial agentsAL-QAWASMEH RAED H·Filed 2010·Granted Mar 12, 2013·8 cites·15 claims
- 0286US8148392B22-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancerHUESCA MARIO·Filed 2006·Granted Apr 3, 2012·16 cites·36 claims
- 0384US6121000AAntitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductaseGENESENSE TECHNOLOGIES INC·Filed 1999·Granted Sep 19, 2000·62 cites·11 claims
- 0484US5998383AAntitumor antisense sequences directed against ribonucleotide reductaseFiled 1997·Granted Dec 7, 1999·66 cites·31 claims
- 0583US8987305B22,4,5-trisubstituted imidazoles and their use as anti-microbial agentsAPTOSE BIOSCIENCES INC·Filed 2013·Granted Mar 24, 2015·3 cites·57 claims
- 0681US7884120B22,4,5-trisubstituted imidazoles and their use as anti-microbial agentsLORUS THERAPEUTICS INC·Filed 2003·Granted Feb 8, 2011·11 cites·20 claims
- 0778US7405205B2Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductaseLORUS THERAPEUTICS INC·Filed 2003·Granted Jul 29, 2008·4 cites·73 claims
- 0877US8287851B2Use of interleukin 17E for the treatment of cancerWRIGHT JIM A·Filed 2006·Granted Oct 16, 2012·6 cites·31 claims
- 0976US10080739B2Aryl imidazoles and their use as anti-cancer agentsAPTOSE BIOSCIENCES INC·Filed 2015·Granted Sep 25, 2018·2 cites·22 claims
- 1072US2008279818A1Combination Preparation of a Biological Response Modifier and an Anticancer Agent and Uses ThereofYOUNG AIPING H·Filed 2008·Application pending·0 cites
- 1168US7968526B2Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancerLORUS THERAPEUTICS INC·Filed 2010·Granted Jun 28, 2011·1 cites·19 claims
- 1267US8969372B2Aryl imidazoles and their use as anti-cancer agentsHUESCA MARIO·Filed 2004·Granted Mar 3, 2015·4 cites·14 claims
- 1365US2006034938A1Combination preparation of a biological response modifier and an anticancer agent and uses thereofYOUNG AIPING H·Filed 2005·Application pending·0 cites
- 1459US6566514B1Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growthGENESENSE TECHNOLOGIES INC·Filed 1999·Granted May 20, 2003·16 cites·13 claims
- 1557US2004101511A1Combination preparation of a biological response modifier and an anticancer agent and uses thereofFiled 2001·Application pending·0 cites
- 1657US2007032442A1Vector utilizing ribonuclease reductase UTR and use for inhibiting neoplastic cellsGENESENSE TECHNOLOGIES INC·Filed 2005·Application pending·0 cites
- 1754US9309247B22-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancerAPTOSE BIOSCIENCES INC·Filed 2014·Granted Apr 12, 2016·0 cites·27 claims
- 1854US2005192443A1Biological response modifier for the treatment of cancerLORUS THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 1952US2007274947A1Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of CancerYOUNG AIPING H·Filed 2004·Application pending·0 cites
- 2050US6417169B1Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growthGENESENSE TECHNOLOGIES INC·Filed 1999·Granted Jul 9, 2002·7 cites·20 claims
- 2150US2009118205A2Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and uses Thereof in the Treatment of CancerLORUS THERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 2249US8394418B2Combination preparation of a biological response modifier and an anticancer agent and uses thereofYOUNG AIPING·Filed 2011·Granted Mar 12, 2013·0 cites·9 claims
- 2349US2008311126A1Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of CancerGENESENSE TECHNOLOGIES INC·Filed 2005·Application pending·0 cites
- 2447US2003087866A1Suppression of malignancy utilizing ribonucleotide reductase R1GENESENSE TECHNOLOGIES INC·Filed 2002·Application pending·0 cites
- 2547US2002187954A1Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to modulate cell growthGENESENSE TECHNOLOGIES INC·Filed 2002·Application pending·0 cites
- 2644US2008255065A1Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses ThereofGENESENSE TECHNOLOGIES INC·Filed 2005·Application pending·0 cites
- 2742US2010204305A1Small interfering rna molecules against ribonucleotide reductase and uses thereofLORUS THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 2841US2016176876A12-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancerAPTOSE BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 2941US2004198819A1Biological response modifier composition and uses thereofFiled 2002·Application pending·0 cites
- 3038US7087580B2Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growthGENESENSE TECHNOLOGIES INC·Filed 1999·Granted Aug 8, 2006·4 cites·40 claims
- 3136US6610539B1Antisense oligonucleotide sequences as inhibitors of microorganismsGENESENSE TECHNOLOGIES INC·Filed 1998·Granted Aug 26, 2003·3 cites·21 claims
- 3231US6472376B2Suppression of malignancy utilizing ribonucleotide reductase R1GENESENSE TECHNOLOGIES INC·Filed 1998·Granted Oct 29, 2002·0 cites·10 claims
- 3330US7223849B1Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growthGENESENSE TECHNOLOGIES INC·Filed 1997·Granted May 29, 2007·0 cites·52 claims
Join the waitlist — get patent alerts
Get an alert when Aiping H. Young files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →